The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia

Sponsor
Xiangya Hospital of Central South University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04314271
Collaborator
(none)
80
1
2.4
33.8

Study Details

Study Description

Brief Summary

Complete the examination of cardio-pulmonary ultrasound in accordance with the a-ccue process of patients with novel coronavirus bedside. To summarize and analyze the characteristics of cardiopulmonary ultrasound in patients with novel coronavirus pneumonia, and assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis. Auto line B is a method which is based on artificial intelligence is used to calculate the lungs ultrasonic B line numbers reviewing the status of patients with lung, and also evaluate patients' lungs using the traditional artificial semi-quantitative method, to evaluate those two kinds of evaluation methods for the evaluation of patients with lung condition effects are consistent or not, and verify consistency of ultrasonic evaluation method and the way of CT evaluation.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    80 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia
    Anticipated Study Start Date :
    Mar 20, 2020
    Anticipated Primary Completion Date :
    May 1, 2020
    Anticipated Study Completion Date :
    May 31, 2020

    Outcome Measures

    Primary Outcome Measures

    1. characteristics of cardiopulmonary ultrasound [30 mins]

      Complete the examination of cardio-pulmonary ultrasound in accordance with the a-ccue process of patients with novel coronavirus bedside. To summarize and analyze the characteristics of cardiopulmonary ultrasound in patients with novel coronavirus pneumonia

    Secondary Outcome Measures

    1. assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis. [2-3weeks]

      assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis.

    Other Outcome Measures

    1. evaluate two kinds of evaluation methods for the evaluation of patients with lung condition effects are consistent or not, and verify consistency of ultrasonic evaluation method and the way of CT evaluation. [3 hours]

      Auto line B is a method which is based on artificial intelligence is used to calculate the lungs ultrasonic B line numbers reviewing the status of patients with lung, and also evaluate patients' lungs using the traditional artificial semi-quantitative method, to evaluate those two kinds of evaluation methods for the evaluation of patients with lung condition effects are consistent or not

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. age >18 years old

    2. identify the patients infected with novel coronavirus pneumonia;

    3. the patient completed CT examination;

    4. sign the informed consent.

    Exclusion Criteria:
    1. age < 18;

    2. those who cannot complete cardiopulmonary ultrasound according to the a-ccue process;

    3. the patient or his guardian requests to withdraw from the researcher;

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Xiangya Hospital, Central South University Changsha Hunan China 410000

    Sponsors and Collaborators

    • Xiangya Hospital of Central South University

    Investigators

    • Study Chair: Zhang Li Na, MD, Xiangya Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Xiangya Hospital of Central South University
    ClinicalTrials.gov Identifier:
    NCT04314271
    Other Study ID Numbers:
    • 202003028
    First Posted:
    Mar 19, 2020
    Last Update Posted:
    Mar 19, 2020
    Last Verified:
    Mar 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 19, 2020